If the clinical effects of trastuzumab on tumour masses are mainly derived from ADCC, which could lose its efficacy as the tumour grows, it is possible that clinical benefits may decrease during extended follow-up and would thus benefit from combinatorial use of Erb-hcAb, on the basis of a different mechanism of action. Here, ESR2 is linked to neoplasm.